Navigation Links
A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)

MS is performed.(Both are dominated by the fragment ion at m/z 207.2.)

In setting the quantitation measurement through the resulting MRM transitions (321.3 > 207.2 for MPA and 514.3 > 207.2 for MPAG), it is important to distinguish that the chromatographic peak seen at the transition 514.3 > 207.2 and corresponding to MPAG is coincident with a chromatographic peak at the same retention time, but obtained through the transition (321.3 > 207.2) specific for MPA (Figure 6). This is determined to be MPAG in-source fragmenting into free MPA, making it clear that chromatographic separation is extremely important in segregating the endogenous MPA in the specimen from the MPA derived from the in-source fragmentation of MPAG.

The modified configuration described here makes it possible to include the analytes CsA, TAC, SIR, EVE, and the additional internal standard (CsD) into the method and quantitate them simultaneously whenever they are present in the same specimen. (MPA is generally analyzed in plasma while the rest of the compounds are quantitated in whole blood). Figure 7 shows the applicability of the method to real samples. In these optimized conditions, the total run time is approximately 5 minutes per sample.

Figure 8 describes the obtained linearity for the samples in the range 0.5 15 ug/mL and Figure 9 gives proof of the intra-run reproducibility on a quality control plasma sample (Level I, Recipe-Munich, Reference Value 0.48 ug/mL). Deviation from the mean value is restricted to 0.5 %.The estimated detection limit on the API 3200 using this protocol is approximately 0.03 μg/mL plasma.

Figure 10 shows the correlation obtained when MPA quantitation is compared with a commercially available HPLC-UV assay.

Conclusion

The modified method described in this application note (1, 2) has been demonstrated to be:

<
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Detection and Identification of Phosphorylation Sites in Proteins Using LC/MS/MS with Neutral Fragment Loss Mapping
2. The Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) by LC/MS/MS Using an Atmospheric Pressure Photoionization Source
3. HPLC/MS/MS Analysis of Bitter Acids in Hops and Beer
4. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
5. The combination of monolithic columns and modern HPLC/MS/MS instrumentation for high chromatographic throughput and sensitive detection of beta-agonists
6. Determination of Polar Organophosphorus Pesticides in Aqueous Samples by Direct Injection Using HPLC/MS/MS
7. Detection of nitrofurane metabolites in food with HPLC/MS/MS
8. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
9. Determination of the Chloramphenicol residues in milk and milk products using LC/MS/MS
10. High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS
11. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
Post Your Comments:
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... (OTC Bulletin Board: ACEL) today reported that it has ... Drug Administration (FDA) to discuss the company,s planned submission ... Drug Application (NDA) for the treatment of unresectable malignant ... FDA provided guidance to the company recommending that an ...
... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities for ... world,s leading pharmaceutical companies, today announced the signing of ... an extension of a current U.S. oncology clinical trial ...
... FORT LAUDERDALE, Fla., Jan. 27 Imaging ... in laser optical breast imaging, will exhibit the CT Laser ... January 26-29, 2009, in Dubai, United Arab Emirates (UAE). ... will select new distributors for the UAE and intends to ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 2Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 3Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference 2
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... particles one-billionth of a meter in size can be ... brain cancer. What's more, these nanoparticles can be used ... them, according to researchers at the University of Michigan ... Photofrin along with iron oxide into nanoparticles that would ...
... soul," corneas are the panes in those windows. They shield ... the eye's outermost lens, contributing up to 75 percent of ... at the annual meeting of the American Chemical Society, chemical ... that's finding its way into artificial corneas. It's a hydrogel, ...
... in monoclonal antibody research for oncology offers a ... of antibody therapies against solid tumors. Writing in ... http://www.interscience.wiley.com/cancer-newsroom ), a peer-reviewed journal of the American ... of cancers involve solid tumors, but only 25 ...
Cached Biology News:U-M researchers use nanoparticles to target brain cancer 2U-M researchers use nanoparticles to target brain cancer 3An artificial cornea is in sight, thanks to biomimetic hydrogels 2An artificial cornea is in sight, thanks to biomimetic hydrogels 3An artificial cornea is in sight, thanks to biomimetic hydrogels 4Report calls for improved monoclonal antibodies against solid tumors 2
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: